We only have this paper's title and publication details.
Read it at the sourceRandomized trial demonstrates that high-dose resveratrol reduces intestinal and hepatic lipoprotein production in overweight and obese men, suggesting potential cardiometabolic benefits.
www.clinicaltrials.gov. Unique identifier: NCT01451918.
No takes yet. Share an insight, caveat, or question.
Dash et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: